Brean Capital Reiterates Buy On Inovio As More Key Clinical Results Coming In 2015
Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Inovio Pharmaceuticals (NASDAQ:INO) with a $20, following the company’s second-quarter financial results and update on its pipeline.
Aschoff wrote, “After the readout of 36-week data from its Phase 2 trial of VGX-3100 for cervical dysplasia, Inovio is now awaiting the likely 3Q15 readout of 88-week data, and then will conduct an EOP2 meeting with the FDA in 2H15. Inovio expects to then initiate a registrational Phase 3 trial in cervical dysplasia in early 2016. The Phase 2 primary endpoint, histopathological regression of CIN2/3 to CIN1 or no disease at week 36, was achieved in 49.5% patients on VGX-3100 versus 30.6% patients on placebo (p<0.025). We look forward to the publication of more detailed 36-week results, especially immunogenicity data hopefully showing overlap between immune response and clinical benefit. Two Phase 1/2a trials evaluating INO-3112 (a combination of VGX-3100 and an IL-12 therapy) in HPV-positive cervical cancer and head and neck cancer are also ongoing. Inovio also launched a compassionate Phase 1 trial of INO-3106 alone or in combination with an IL-12 therapy in patients with HPV-6 associated aerodigestive cancer who have exhausted other treatment options (chemotherapy, radiation and surgery).”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 12.7% and a 62.0% success rate. Aschoff has a -20.8% average return when recommending INO, and is ranked #173 out of 3367 analysts.